{"id":"NCT02845674","sponsor":"Sun Pharmaceutical Industries Limited","briefTitle":"An Open-Label Extension of a Phase 3 Study of OTX-101 in the Treatment of Keratoconjunctivitis Sicca","officialTitle":"An Open-Label Extension of a Randomized, Multicenter, Double-Masked, Vehicle-Controlled Study of the Safety and Efficacy of OTX-101 in the Treatment of Keratoconjunctivitis Sicca","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2016-07-29","primaryCompletion":"2017-08-15","completion":"2017-08-15","firstPosted":"2016-07-27","resultsPosted":"2018-12-14","lastUpdate":"2021-11-19"},"enrollment":258,"design":{"allocation":"NA","model":"SINGLE_GROUP","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["Keratoconjunctivitis Sicca"],"interventions":[{"type":"DRUG","name":"OTX-101 0.09%","otherNames":["Seciera"]}],"arms":[{"label":"OTX-101 0.09%","type":"EXPERIMENTAL"}],"summary":"This is a safety extension enrolling subjects participating in Study OTX-101-2016-001 (NCT02688556)","primaryOutcome":{"measure":"Adverse Events","timeFrame":"40 weeks","effectByArm":[{"arm":"Group 1","deltaMin":68,"sd":null},{"arm":"Group 2","deltaMin":81,"sd":null}],"pValues":[]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":1,"exclusionCount":null},"locations":{"siteCount":0,"countries":[]},"refs":{"pmids":["33469259"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":4,"n":129},"commonTop":["Instillation site pain","Conjunctival hyperaemia","Punctate keratitis","Vitreous detachment","Blepharitis"]}}